Pancreatic Cancer: Our Clinical Trials

Memorial Sloan Kettering Cancer Center conducts clinical trials that investigate new chemotherapy drugs and combinations of drugs, surgical and radiation therapy techniques, imaging technologies, and other approaches for the diagnosis and treatment of pancreatic cancer.

Because advancing cancer care is an important part of our mission, choosing Memorial Sloan Kettering for your cancer care may offer you access to new therapies that are not widely available at other hospitals. Our clinical research team can help to determine whether a clinical trial would be right for you. We will work with your pancreatic cancer treatment team to ensure that you receive the best possible care.  

Here you can find a continually updated listing of pancreatic cancer clinical trials at Memorial Sloan Kettering Cancer Center that are currently enrolling new patients. To learn more about a study, choose from the list below.

Showing 17 trials
Title Investigatorsort icon
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
Relapsed/Refractory
[Protocol 13-187]
Callahan, Margaret, MD, PhD
A Phase IA/IB Study of RO5509554 Alone and with Paclitaxel in Patients with Advanced Solid Tumors
[Protocol 14-086]
D'Angelo, Sandra, MD
Coping with Cancer II
[Protocol 14-048]
Epstein, Andrew, MD
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
[Protocol 10-083]
Goodman, Karyn, MD
A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
[Protocol 14-111]
Harding, James, MD
A Phase I Study of ADI-PEG 20 plus FOLFOX in Patients with Advanced Digestive Cancers
[Protocol 14-153]
Harding, James, MD
Memorial Sloan-Kettering Cancer Center Pancreatic Tumor Registry
[Protocol 02-102]
Kurtz, Robert, MD
A Phase IB Study of ADI-PEG 20 plus Nab-Paclitaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer
[Protocol 14-133]
Lowery, Maeve, MD
A Phase I Study of DLYE5953A in Patients with Advanced or Persistent Solid Tumors
[Protocol 14-089]
Modi, Shanu, MD
A Phase III Study Comparing Gemcitabine plus nab-Paclitaxel to Gemcitabine Alone After Pancreatic Cancer Surgery
[Protocol 14-120]
O'Reilly, Eileen, MD
A Phase III Study of Capecitabine with Ruxolitinib or Placebo to Treat Advanced Pancreatic Cancer
[Protocol 14-190]
O'Reilly, Eileen, MD
Two Phase II Studies of Veliparib for Pancreatic Cancer with a BRCA or PALB2 Mutation: Gemcitabine...
[Protocol 12-045]
O'Reilly, Eileen, MD
A Phase I/II Study of M402 in Combination with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-078]
O'Reilly, Eileen, MD
A Phase IB/II Study of OMP-59R5 with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
[Protocol 12-234]
O'Reilly, Eileen, MD
A Phase II Study of Temozolomide Alone and with Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
[Protocol 13-194]
Reidy-Lagunes, Diane, MD
A Two-Stage Pilot Study of PEGPH20 and Cetuximab in Patients with Pancreatic Cancer When Given Before Tumor Removal
[Protocol 14-039]
Yu, Kenneth, MD